Vera Therapeutics, Inc. (VERA)
Automate Your Wheel Strategy on VERA
With Tiblio's Option Bot, you can configure your own wheel strategy including VERA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VERA
- Rev/Share 0.0
- Book/Share 8.4025
- PB 2.7063
- Debt/Equity 0.1018
- CurrentRatio 27.6823
- ROIC -0.3278
- MktCap 1450225308.0
- FreeCF/Share -2.4566
- PFCF -9.2717
- PE -8.252
- Debt/Assets 0.0893
- DivYield 0
- ROE -0.4059
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | VERA | H.C. Wainwright | -- | Buy | -- | $75 | May 5, 2025 |
| Initiation | VERA | Wolfe Research | -- | Outperform | -- | $49 | Feb. 4, 2025 |
| Initiation | VERA | Goldman | -- | Buy | -- | $58 | Jan. 28, 2025 |
| Initiation | VERA | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
News
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Published: June 12, 2025 by: MarketBeat
Sentiment: Positive
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
Read More
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance LLC (“Oxford”). The new credit facility will replace Vera's existing $50 million credit facility. The initial funding of the new credit facility will be in a principal amount of $75 million and is expected to occur on June 4, 2025.
Read More
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data
Published: June 02, 2025 by: Benzinga
Sentiment: Positive
Vera Therapeutics, Inc. VERA saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.
Read More
Vera shares skyrocket as kidney disease drug succeeds in late-stage trial
Published: June 02, 2025 by: Reuters
Sentiment: Positive
Shares of Vera Therapeutics soared 82% on Monday, after the company said its experimental drug helped significantly reduce excess levels of harmful proteins in the urine of kidney disease patients in a late-stage study.
Read More
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.
Read More
Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
I am maintaining my 'Hold' rating on Vera Therapeutics from January 2024 despite initial strong stock gains and positive Phase 2b data for atacicept, before a collapse in stock value. In my last note, I cited high short interest, lack of other assets, and long timeline for approval as key reasons for caution. Vera's pivotal Phase 3 trial data is likely to be shared in the next month, however, presenting a potentially momentous catalyst, and an approval shot in 2026.
Read More
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q 2025 Expanded atacicept development program across multiple autoimmune kidney diseases is underway BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2025.
Read More
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025) U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN).
Read More
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025.
Read More
About Vera Therapeutics, Inc. (VERA)
- IPO Date 2021-05-14
- Website https://veratx.com
- Industry Biotechnology
- CEO Dr. Marshall W. Fordyce M.D.
- Employees 152